Aflibercept (Eylea) Biosimilars Pipeline Review 2024: Patents are Due to Run out from 2023 to 2032
February 23, 2024 07:32 ET
|
Research and Markets
Dublin, Feb. 23, 2024 (GLOBE NEWSWIRE) -- The "Aflibercept (Eylea) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information on...
Stakes Are High for Regeneron's Eylea HD as Genentech's Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to Spherix Global Insights
February 08, 2024 15:17 ET
|
Spherix Global Insights
Exton, Pennsylvania, Feb. 08, 2024 (GLOBE NEWSWIRE) -- As Age-Related Macular Degeneration (AMD) Awareness Month unfolds, illuminating the visual challenges faced by millions of Americans with AMD,...
Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors
January 08, 2024 09:45 ET
|
Curative Biotechnology, Inc.
Appointment of Independent Director Nominee to become effective upon approval by and listing of common stock on a National Exchange Boca Raton, FL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Curative...
Rate of Switching from Regeneron’s Eylea to Genentech’s Vabysmo Doubled Over Past Year for Diabetic Macular Edema
November 01, 2023 14:55 ET
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 01, 2023 (GLOBE NEWSWIRE) -- As U.S. ophthalmologists increasingly embrace a wider array of treatment options, the landscape of the diabetic macular edema (DME) market has...
Global Eylea Market to Reach $9.33 Billion by 2027, Driven by Increasing Prevalence of Ocular Diseases
July 25, 2023 05:23 ET
|
Research and Markets
Dublin, July 25, 2023 (GLOBE NEWSWIRE) -- The "Eylea Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers, and senior...
Anti-Vascular Endothelial Growth Factor Therapeutics market is expected to reach a US$13.1 Bn by 2032 at a CAGR 1% | According PMR
December 20, 2022 08:10 ET
|
Persistence Market Research
New York, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Anti-Vascular Endothelial Growth Factor Therapeutics market is expected to reach a US$ 455 Mn by 2032 at a CAGR 1% | According PMR Anti-Vascular...
The Worldwide Anti-Vascular Endothelial Growth Factor Therapeutics Industry is Expected to Reach $13.3 Billion by 2030
June 03, 2022 06:58 ET
|
Research and Markets
Dublin, June 03, 2022 (GLOBE NEWSWIRE) -- The "Anti-Vascular Endothelial Growth Factor Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Product; By Disease; By Region; Segment...
Clearside Biomedical, Inc. Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion
July 26, 2016 07:30 ET
|
Clearside Biomedical, Inc.
78% of Patients Required No Additional Treatment in the Trial Arm with Concomitant Suprachoroidally Administered Zuprata™ and Intravitreally Administered Eylea®Patients Reached an Average BCVA...
Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc.; Raises Price Target to $14.00
July 31, 2013 09:15 ET
|
Vista Partners LLC
SAN FRANCISCO, CA--(Marketwired - Jul 31, 2013) - Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (NASDAQ: OHRP) ("The Company" or "OHR") and raised its...
Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc.; Target Price $3.50
October 17, 2012 09:15 ET
|
Vista Partners LLC
SAN FRANCISCO, CA--(Marketwire - Oct 17, 2012) - Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (OTCBB: OHRP) ("The Company" or "OHR") with a twelve month...